TEVA — Teva Pharmaceutical Industries

Is TEVA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of November 17, 2026

Teva Pharmaceutical Industries (TEVA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $42.57. The rating moved from Neutral to Overbought on November 16, 2026.

See all overbought Healthcare stocks →

AI analysis

Teva Pharmaceutical Industries (TEVA) combines a leading generics franchise with a growing specialty product set, delivering steady cash flows while pursuing margin improvement and portfolio upgrades. The recent FDA clearance for an at‑home agitation treatment enhances near‑term specialty revenue visibility and supports commercial upside. Macroeconomic caution and defensive flows into large‑cap pharma lend relative stability to share performance, but the company remains exposed to elevated leverage, secular generic pricing pressure, regulatory compliance risk and potential litigation. Near‑term upside is driven by specialty rollout execution, further margin recovery and disciplined balance‑sheet actions; downside is tied to weaker pricing, missed execution or material reimbursement/ regulatory developments.

Key factors

  • Large, diversified generics and specialty portfolio providing stable, recurring cash flows
  • Recent FDA clearance of a newly acquired at‑home agitation treatment expands specialty product revenue and validates M&A pipeline
  • Sector defensive flows into large‑cap pharma support downside protection in risk‑off environments
  • Ongoing cost‑reduction and working‑capital initiatives that improve margin and free cash flow conversion
  • Global scale in manufacturing and distribution that sustains generic market share and price competitiveness

Risks

  • High leverage and debt-servicing requirements that constrain capital deployment and increase sensitivity to cash‑flow swings
  • Continued generic pricing pressure and payer cost controls that can compress margins and reduce volume/value for legacy products
  • Regulatory and reimbursement headwinds (including Medicare integrity actions) that could alter product economics or increase compliance costs
  • Patent challenges, litigation exposure and biosimilar competition that can accelerate revenue erosion for key molecules
  • Execution risk around integration of acquisitions and commercialization of recently acquired specialty assets

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TEVA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.